Purchase this article with an account.
B.K. Ambati, N. Singh, J. Witta, M. Nozaki, J.Z. Baffi, B. Raisler, S. Rashid, T. Suthar, A. Orecchia, J. Ambati; In situ Ablation of sFLT Disrupts the Corneal Anti–Angiogenic Barrier . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4501.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To determine if soluble FLT mediates corneal avascularity. Methods: A series of mouse and human corneal specimens were examined for the presence of soluble FLT. Binding of VEGF to sFLT was assessed by immunoprecipitation.In situ ablation of sFLT was performed in human cells and mouse corneas. Plasmid–directed replenishment of sFLT was performed to assess whether avascularity could be preserved. Results: sFLT is highly expressed in mouse and human corneal epithelium and also expressed in corneal stroma. It is downregulated in neovascularized human corneas. VEGF is sequestered by VEGF in normal cornea but much less so in neovascularized corneas. In situ ablation of sFLT breaches corneal avascularity in the mouse. These effects are effectively countered by plasmid–directed restoration of sFLT. Conclusions: sFLT mediates corneal avascularity.
This PDF is available to Subscribers Only